Gene Therapy Bioassays Market Expansion Is Reshaping Competitive Dynamics Across The Industry
Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.
Gene Therapy Bioassays Market Revenue Growth Supported By A CAGR Of 2.62% Through 2030
The gene therapy bioassays market has experienced significant growth in recent years. It is projected to expand from $1.21 billion in 2025 to $1.41 billion in 2026, achieving a compound annual growth rate (CAGR) of 16.5%. The expansion witnessed in previous periods can be attributed to the increase in gene therapy research programs, the scaling up of viral vector manufacturing, a rise in clinical trial activity, the implementation of standardized bioassay protocols, and growing regulatory scrutiny on gene therapy products.
The gene therapy bioassays market size is set to experience substantial expansion in the upcoming years. It is projected to climb to $2.62 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 16.7%. This anticipated growth is linked to the increasing commercialization of gene therapies, a rising need for high-throughput bioassay solutions, the broadening field of personalized genetic medicine, growing investments in advanced cell and gene therapy pipelines, and a greater emphasis on assay automation and reproducibility. Significant trends expected during this period involve the increasing adoption of cell-based potency assays, a rising demand for viral vector characterization tests, the growing use of automated bioassay platforms, the expansion of regulatory-compliant assay validation, and an enhanced focus on functional gene expression analysis.
Download A Free Sample Report For Comprehensive Market Insights:
Gene Therapy Bioassays Market Growth Momentum: Which Factors Are Influencing Demand?
An increasing volume of gene therapy clinical trials is projected to stimulate growth in the gene therapy bioassays market. These trials are designed to evaluate the safety, efficacy, and biological performance of gene-based treatments in human subjects. The expansion of these trials is fueled by intensified research and development efforts and rising investment from biopharmaceutical companies aiming to address unmet medical needs via innovative genetic therapies. Gene therapy bioassays facilitate clinical development by offering essential analytical tests to assess biological activity, potency, safety, and mechanism of action at each development stage, with regulatory requirements escalating as programs advance through clinical phases. For instance, in January 2026, the Bioindustry Association (BIA), a UK-based national trade association, reported that the UK had 193 ongoing advanced therapy clinical trials, with over 80% concentrating on gene therapies. Thus, the proliferation of gene therapy clinical trials is a significant driver for the growth of the gene therapy bioassays market.
Gene Therapy Bioassays Market Segment Performance And Strategic Opportunities
The gene therapy bioassays market covered in this report is segmented –
1) By Product Type: Cell-Based Assays; Viral Vector-Based Assays; Non-Viral Vector-Based Assays; Other Product Types
2) By Service Type: Assay Development Services; Assay Validation Services; Quality Control Testing Services; Regulatory Support Services; Data Analysis And Reporting Services; Custom Bioassay Design Services
3) By Application: Research And Development; Clinical Testing; Quality Control; Other Applications
4) By End User: Biotechnology Companies; Pharmaceutical Companies; Contract Research Organizations; Academic And Research Institutes; Regulatory Laboratories
Subsegments:
1) By Cell-Based Assays: Reporter Gene Expression Assays; Cell Viability And Cytotoxicity Assays; Transduction Efficiency Assays; Functional Potency Cell Assays; Cellular Uptake And Localization Assays
2) By Viral Vector-Based Assays: Adeno Associated Virus Vector Assays; Lentiviral Vector Characterization Assays; Retroviral Vector Titer Assays; Vector Genome Integrity Assays; Infectivity And Transduction Assays
3) By Non-Viral Vector-Based Assays: Plasmid Deoxyribonucleic Acid Delivery Assays; Lipid Nanoparticle Transfection Assays; Polymeric Carrier Efficiency Assays; Physical Gene Delivery Evaluation Assays; Non Viral Vector Stability Assays
4) By Other Product Types: Immunogenicity Assessment Assays; Biodistribution And Persistence Assays; Safety And Toxicity Bioassays; Analytical Method Development Assays; Custom Gene Therapy Bioassays
Gene Therapy Bioassays Market Trends Reshaping Industry Growth
Major companies within the gene therapy bioassays market are increasingly incorporating artificial intelligence and machine learning into bioassay analysis. This integration, notably seen in AI-enabled digital PCR data interpretation, aims to enhance accuracy, reduce experimental variability, accelerate result turnaround, and optimize the assessment of therapeutic efficacy and safety in gene therapy development. AI-powered dPCR data interpretation utilizes advanced algorithms to automate result analysis, differentiate true signals from background noise, and precisely quantify viral genomes or vector copy numbers with minimal human intervention. For instance, in April 2025, QIAGEN N.V., a Germany-based molecular diagnostics company, launched expanded QIAcuity lentivirus solutions, including the QIAcuity RCL Quant Kit and CGT dPCR assays. These solutions feature algorithm-driven absolute quantification, compatibility for multiplex and singleplex assays in vector genome and vector copy number analysis, and software-assisted data analysis workflows designed to support regulatory-compliant decision-making in gene therapy bioassay applications.
Gene Therapy Bioassays Market Key Players: Which Companies Shape Industry Competition?
Major companies operating in the gene therapy bioassays market are Boehringer Ingelheim BioXcellence, AGC Biologics, ICON plc, Lonza Group AG, SGS SA, Eurofins Scientific SE, WuXi AppTec, Charles River Laboratories International Inc., Catalent Inc, Recipharm AB, KBI Biopharma, Syngene International Limited, QPS Holdings LLC, BioAgilytix Labs (operationally independent CRO), Oxford Biomedica plc, Viralgen Vector S.L., ProtaGene Inc., Center for Breakthrough Medicines, RoslinCT, Immunologix Labs, Genezen Laboratories
Access The Complete Gene Therapy Bioassays Market Report:
Gene Therapy Bioassays Market Leading Geography: Which Region Generates The Most Revenue?
North America was the largest region in the gene therapy bioassays market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gene therapy bioassays market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
